Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Marker Therapeutics Inc | MRKR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 4.24 | 0.00 | 0.00 | 0.00 | 4.24 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 4.23 | 4.39 | 0.16 | 3.64% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
Marker Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 193.64M | 45.67M | $ -147.96M | -7.75 | - | 30.45M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 3.00 | 33.30% |
Marker Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRKR Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.52 | 4.74 | 4.1 | 4.3077 | 204k | -0.28 | -6.19% |
| 1 Month | 5.93 | 5.99 | 4.1 | 4.7187 | 186k | -1.69 | -28.50% |
| 3 Months | 5.13 | 6.54 | 3.97 | 4.9889 | 292k | -0.89 | -17.35% |
| 6 Months | 5.28 | 9.17 | 3.97 | 6.2364 | 434k | -1.04 | -19.70% |
| 1 Year | 9.06 | 9.9 | 3.97 | 6.2335 | 371k | -4.82 | -53.20% |
| 3 Years | 10.01 | 10.25 | 3.97 | 6.2438 | 369k | -5.77 | -57.64% |
| 5 Years | 10.01 | 10.25 | 3.97 | 6.2438 | 369k | -5.77 | -57.64% |
Marker Therapeutics Description
| Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from our MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. |
